Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 13/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 4/20 | 0.59 |
| ▸ | MMP9 | P14780 | 4/20 | 0.59 |
| ▸ | MMP8 | P22894 | 4/20 | 0.59 |
| ▸ | MMP13 | P45452 | 3/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190883 | 0.90 | NPBWR1 (0.80) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3193088 | 0.86 | NPBWR1 (0.80) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5566197 | 0.86 | NPC1 (0.78) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29848847 | 0.86 | NPBWR1 (0.57) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17255170 | 0.85 | NPC1 (0.50) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3335995 | 0.83 | NPBWR1 (0.81) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6327841 | 0.82 | NPC1 (0.72) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL28761269 | 0.82 | RAB9A (0.80) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12470997 | 0.82 | NPBWR1 (0.82) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL31474746 | 0.82 | NPC1 (0.72) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | MAKOVEC FRANCESCO | 2010-05-13 | — | — | US | disclosed |
| US-7674809-B2 | Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM S.P.A. (IT) | 2010-03-09 | — | — | US | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | NOS3, NOS1, NOS2 | NPBWR1 323/4885MAPT 4542/4885RAB9A 2198/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | NPBWR1 323/4885MAPT 4542/4885RAB9A 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.